Three-dimensional stereotactic surface projection in the statistical analysis of single photon emission computed tomography data for distinguishing between Alzheimer's disease and depression

作     者：Eiji Kirino 

作者机构：Department of Psychiatry Juntendo University School of Medicine Department of Psychiatry Juntendo University Shizuoka Hospital Juntendo Institute of Mental Health 

出 版 物：《World Journal of Psychiatry》 (世界精神病学杂志)

年 卷 期：2017年第7卷第2期

页      面：121-127页

核心收录：

学科分类：1002[医学-临床医学] 100203[医学-老年医学] 10[医学] 

基　　金：Grants-in-Aid for Scientific Research Funding Source: KAKEN 

主　　题：Alzheimer’s disease Three-dimensional stereotactic surface projection Single photon emission computed tomography Pseudo-dementia Depression 

摘      要：AIM To evaluate usefulness of single photon emission computed tomography(SPECT) with three-dimensional stereotactic surface projection(3D-SSP) in distinguishing between Alzheimer s disease(AD) and *** We studied 43 patients who presented with both depressive symptoms and memory disturbance. Each subject was evaluated using the following:(1) the Minimal Mental State Examination;(2) the Hamilton Rating Scale for Depression;(3) Clinical Global Impression-Severity scale(CGI-S); and(4) SPECT imaging with *** The MMSE scores correlated significantly with the maximum Z-scores of AD-associated regions. CGI-S scores correlated significantly with the maximum Z-scores of depression-associated regions. Factor analysis identified three significant factors. Of these, Factor 1 could be interpreted as favouring a tendency for AD, Factor 2 as favouring a tendency for pseudo-dementia, and Factor 3 as favouring a depressive *** We investigated whether these patients could be categorized as types: Type A(true AD), Type B(pseudodementia), Type C(occult AD), and Type D(true depression). The factor scores in factor analysis supported the validity of this classification. Our results suggest that SPECT with 3D-SSP is highly useful for distinguishing between depression and depressed mood in the early stage of AD.